Details werden geladen...
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium | The Manila Times
Milestone achievement advances potential first FDA-approved disease-modifying therapy for pterygium, a condition affecting just under one billion people globally, including 15 million people in the U.S.
Ähnliche Seiten
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
https://www.finanznachrichten.de/nachrichten-2026-05/68561841-merck-announces-first-patient-dosed-in-phase-3-study-for-investigational-antibody-drug-conjugate-in-colorectal-cancer-004.htmBial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson's
https://www.finanznachrichten.de/nachrichten-2026-05/68589222-bial-announces-completion-of-phase-2b-activate-study-with-bia-28-6156-in-gba1-associated-parkinson-s-004.htm
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096 | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/herantis-reports-positive-fda-feedback-and-finalizes-phase-2a-study-design-for-her-096/2356634Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/enlivex-announces-dosing-of-first-patient-in-the-united-states-as-part-of-its-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis/2346178Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/junshi-biosciences-announces-primary-endpoints-met-in-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc/2352231